A review of the clinical uses of ximelagatran in thrombosis syndromes

被引：6

作者：

Bergsrud, EA ^{[1
]}

Gandhi, PJ ^{[1
]}

机构：

[1] UMass Mem Med Ctr, Dept Pharm, Worcester, MA 01655 USA

来源：

JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2003年 / 16卷 / 03期

关键词：

ximelagatran; melagatran; direct thrombin inhibitors;

D O I：

10.1023/B:THRO.0000024056.84909.b0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ximelagatran, an oral direct thrombin inhibitor, has been investigated for the prevention and treatment of venous thromboembolism as well as for anticoagulation in atrial fibrillation. Unique properties of ximelagatran are that it is a prodrug, it does not require routine laboratory monitoring and it has minimal drug interactions. The dose of ximelagatran needs to be modified in patients with renal failure; however, dosing guidelines in this specific patient population have not been established. Preliminary and emerging data suggest that ximelagatran is superior or at least as effective as low molecular weight heparins and warfarin in the setting of venous thromboembolism prevention and treatment. Ximelagatran has comparable bleeding rates to low molecular weight heparins and warfarin; however, it is associated with transient elevations in hepatic transaminases.

引用

页码：175 / 188

页数：14

共 41 条

[1]

Béguin S, 1999, HAEMOSTASIS, V29, P170

[2] Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions [J].

Bredberg, E ;

Andersson, TB ;

Frison, L ;

Thuresson, A ;

Johansson, S ;

Eriksson-Lepkowska, M ;

Larsson, M ;

Eriksson, UG .

CLINICAL PHARMACOKINETICS, 2003, 42 (08) :765-777

[3] Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug [J].

Clement, B ;

Lopian, K .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) :645-651

[4] Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study [J].

Colwell, CW ;

Berkowitz, SD ;

Davidson, BL ;

Lotke, PA ;

Ginsberg, JS ;

Lieberman, JR ;

Neubauer, J ;

McElhattan, JL ;

Peters, GR ;

Francis, CW .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (10) :2119-2130

[5] Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement:: the METHRO II randomised trial [J].

Eriksson, B ;

Bergqvist, D ;

Kälebo, P ;

Dahl, OE ;

Lindbratt, S ;

Bylock, A ;

Frison, L ;

Eriksson, UG ;

Welin, L ;

Gustafsson, D .

LANCET, 2002, 360 (9344) :1441-1447

[6]

Eriksson BI, 2003, THROMB HAEMOSTASIS, V89, P288

[7]

Eriksson BI, 2002, THROMB HAEMOSTASIS, V87, P231

[8]

Eriksson H, 1999, THROMB HAEMOSTASIS, V81, P358

[9] A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis:: THRIVE I [J].

Eriksson, H ;

Wählander, K ;

Gustafsson, D ;

Welin, LT ;

Frison, L ;

Schulman, S .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (01) :41-47

[10] Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans [J].

Eriksson, UG ;

Bredberg, U ;

Hoffmann, KJ ;

Thuresson, A ;

Gabrielsson, M ;

Ericsson, H ;

Ahnoff, M ;

Gislén, K ;

Fager, G ;

Gustafsson, D .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :294-305

← 1 2 3 4 5 →